WO2001024777A1 - Coated solid dosage forms - Google Patents
Coated solid dosage forms Download PDFInfo
- Publication number
- WO2001024777A1 WO2001024777A1 PCT/EP2000/009576 EP0009576W WO0124777A1 WO 2001024777 A1 WO2001024777 A1 WO 2001024777A1 EP 0009576 W EP0009576 W EP 0009576W WO 0124777 A1 WO0124777 A1 WO 0124777A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- released
- drug
- hours
- hours exposure
- solid dose
- Prior art date
Links
- 0 C*C(C(*)C(C)N=O)C(C(C(*)C(C)*)O)O Chemical compound C*C(C(*)C(C)N=O)C(C(C(*)C(C)*)O)O 0.000 description 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ518033A NZ518033A (en) | 1999-10-04 | 2000-09-29 | Delayed release/slow release drugs lacking enteric coat |
AU10206/01A AU783911B2 (en) | 1999-10-04 | 2000-09-29 | Coated solid dosage forms |
CA002383306A CA2383306A1 (en) | 1999-10-04 | 2000-09-29 | Novel pharmaceutical compositions |
HU0203311A HUP0203311A3 (en) | 1999-10-04 | 2000-09-29 | New pharmaceutical compositions of prolonged effect |
MXPA02003440A MXPA02003440A (en) | 1999-10-04 | 2000-09-29 | Coated solid dosage forms. |
JP2001527776A JP2003510346A (en) | 1999-10-04 | 2000-09-29 | New pharmaceutical composition |
EP00971305A EP1217992A1 (en) | 1999-10-04 | 2000-09-29 | Coated solid dosage forms |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9923436.1A GB9923436D0 (en) | 1999-10-04 | 1999-10-04 | Pharmaceutical compositions |
GB9923436.1 | 1999-10-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001024777A1 true WO2001024777A1 (en) | 2001-04-12 |
Family
ID=10862090
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2000/009576 WO2001024777A1 (en) | 1999-10-04 | 2000-09-29 | Coated solid dosage forms |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP1217992A1 (en) |
JP (1) | JP2003510346A (en) |
CN (1) | CN1402630A (en) |
AR (1) | AR025938A1 (en) |
AU (1) | AU783911B2 (en) |
CA (1) | CA2383306A1 (en) |
GB (1) | GB9923436D0 (en) |
HU (1) | HUP0203311A3 (en) |
MX (1) | MXPA02003440A (en) |
NZ (1) | NZ518033A (en) |
TW (1) | TWI233363B (en) |
WO (1) | WO2001024777A1 (en) |
ZA (1) | ZA200203486B (en) |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100434904B1 (en) * | 2002-05-30 | 2004-06-11 | 주식회사 대웅 | Enteric formulations containing stabilized lansoprazole |
EP1462097A1 (en) * | 2003-03-28 | 2004-09-29 | Acme Drugs S.r.l. | Process for the preparation of enteric-coated and /or controlled-release medicaments containing active principles sensitive to gastrointestinal environment |
WO2005020954A2 (en) * | 2003-09-03 | 2005-03-10 | Agi Therapeutics Limited | Proton pump inhibitor formulations, and methods of preparing and using such formulations |
WO2006049565A1 (en) * | 2004-11-04 | 2006-05-11 | Astrazeneca Ab | New modified release tablet formulations for proton pump inhibitors |
WO2006049564A1 (en) * | 2004-11-04 | 2006-05-11 | Astrazeneca Ab | New modified release pellet formulations for proton pump inhibitors |
EP1762231A1 (en) * | 2005-08-19 | 2007-03-14 | Verla-Pharm Arzneimittelfabrik Apotheker H.J. von Ehrlich GmbH & Co. KG | Sustained release magnesium microtablets |
WO2008002567A2 (en) * | 2006-06-27 | 2008-01-03 | Alza Corporation | Methods of treating conditions by sustained release administration of benzimidazole derivatives |
US7790755B2 (en) | 2002-10-16 | 2010-09-07 | Takeda Pharmaceutical Company Limited | Controlled release preparation |
US8852636B2 (en) | 2001-06-01 | 2014-10-07 | Pozen Inc. | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
US8945621B2 (en) | 2009-06-25 | 2015-02-03 | Pozen Inc. | Method for treating a patient at risk for developing an NSAID-associated ulcer |
US9023391B2 (en) | 1999-06-22 | 2015-05-05 | Dexcel Ltd. | Stable benzimidazole formulation |
US9220698B2 (en) | 2008-09-09 | 2015-12-29 | Pozen Inc. | Method for delivering a pharmaceutical composition to patient in need thereof |
US9238029B2 (en) | 2004-06-16 | 2016-01-19 | Takeda Pharmaceuticals U.S.A., Inc. | Multiple PPI dosage form |
US9539214B2 (en) | 2011-12-28 | 2017-01-10 | Pozen Inc. | Compositions and methods for delivery of omeprazole plus acetylsalicylic acid |
EP2827845B1 (en) | 2012-03-22 | 2018-12-26 | Novo Nordisk A/S | Compositions comprising a delivery agent and preparation thereof |
US10933120B2 (en) | 2012-03-22 | 2021-03-02 | Novo Nordisk A/S | Compositions of GLP-1 peptides and preparation thereof |
US10960052B2 (en) | 2010-12-16 | 2021-03-30 | Novo Nordisk A/S | Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl) amino) caprylic acid |
US11033499B2 (en) | 2012-06-20 | 2021-06-15 | Novo Nordisk A/S | Tablet formulation comprising a GLP-1 peptide and a delivery agent |
US11034746B2 (en) | 2011-04-12 | 2021-06-15 | Novo Nordisk A/S | Double-acylated GLP-1 derivatives |
US11123296B2 (en) | 2012-03-22 | 2021-09-21 | Novo Nordisk A/S | Compositions comprising a delivery agent and preparation thereof |
US11833248B2 (en) | 2018-02-02 | 2023-12-05 | Novo Nordisk A/S | Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012518655A (en) * | 2009-02-23 | 2012-08-16 | アプタリス ファーマテック インコーポレイテッド | Controlled release composition comprising a proton pump inhibitor |
CN102846571A (en) * | 2012-09-29 | 2013-01-02 | 南京正科制药有限公司 | Esomeprazole magnesium micro-tablet |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993025204A1 (en) * | 1992-06-16 | 1993-12-23 | Ethypharm | Gastro-protected stable omeprazole compositions in the form of microgranules and process for their production |
WO1994002140A1 (en) * | 1992-07-17 | 1994-02-03 | Astra Aktiebolag | Pharmaceutical composition containing antiulcer agent |
WO1999032093A1 (en) * | 1997-12-22 | 1999-07-01 | Astrazeneca Ab | Oral pharmaceutical pulsed release dosage form |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2571092A (en) * | 1991-09-27 | 1993-04-27 | Fujisawa Pharmaceutical Co., Ltd. | Long-acting preparation |
CN1277550A (en) * | 1997-09-11 | 2000-12-20 | 尼科梅德丹麦有限公司 | Modified release multiple-units compositions of non-steroid anti-inflammatory drug sbstances (NSAIDS) |
JP2000128779A (en) * | 1998-10-20 | 2000-05-09 | Mitsui Chemicals Inc | Controlled release medicine type preparation |
-
1999
- 1999-10-04 GB GBGB9923436.1A patent/GB9923436D0/en not_active Ceased
-
2000
- 2000-09-29 CA CA002383306A patent/CA2383306A1/en not_active Abandoned
- 2000-09-29 HU HU0203311A patent/HUP0203311A3/en unknown
- 2000-09-29 CN CN00816583.1A patent/CN1402630A/en active Pending
- 2000-09-29 NZ NZ518033A patent/NZ518033A/en unknown
- 2000-09-29 EP EP00971305A patent/EP1217992A1/en not_active Withdrawn
- 2000-09-29 AU AU10206/01A patent/AU783911B2/en not_active Ceased
- 2000-09-29 WO PCT/EP2000/009576 patent/WO2001024777A1/en active IP Right Grant
- 2000-09-29 JP JP2001527776A patent/JP2003510346A/en active Pending
- 2000-09-29 MX MXPA02003440A patent/MXPA02003440A/en not_active Application Discontinuation
- 2000-10-02 AR ARP000105197A patent/AR025938A1/en not_active Application Discontinuation
- 2000-10-03 TW TW089120543A patent/TWI233363B/en not_active IP Right Cessation
-
2002
- 2002-05-02 ZA ZA200203486A patent/ZA200203486B/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993025204A1 (en) * | 1992-06-16 | 1993-12-23 | Ethypharm | Gastro-protected stable omeprazole compositions in the form of microgranules and process for their production |
WO1994002140A1 (en) * | 1992-07-17 | 1994-02-03 | Astra Aktiebolag | Pharmaceutical composition containing antiulcer agent |
WO1999032093A1 (en) * | 1997-12-22 | 1999-07-01 | Astrazeneca Ab | Oral pharmaceutical pulsed release dosage form |
Cited By (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9023391B2 (en) | 1999-06-22 | 2015-05-05 | Dexcel Ltd. | Stable benzimidazole formulation |
US9707181B2 (en) | 2001-06-01 | 2017-07-18 | Pozen Inc. | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
US9364439B2 (en) | 2001-06-01 | 2016-06-14 | Pozen Inc. | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
US9345695B2 (en) | 2001-06-01 | 2016-05-24 | Pozen Inc. | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
US9198888B2 (en) | 2001-06-01 | 2015-12-01 | Pozen Inc. | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
US9161920B2 (en) | 2001-06-01 | 2015-10-20 | Pozen Inc. | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
US8865190B2 (en) | 2001-06-01 | 2014-10-21 | Pozen Inc. | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
US8858996B2 (en) | 2001-06-01 | 2014-10-14 | Pozen Inc. | Pharmaceutical compositions for the coordinated delivery of NSAIDS |
US8852636B2 (en) | 2001-06-01 | 2014-10-07 | Pozen Inc. | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
KR100434904B1 (en) * | 2002-05-30 | 2004-06-11 | 주식회사 대웅 | Enteric formulations containing stabilized lansoprazole |
CN101884629B (en) * | 2002-10-16 | 2013-08-21 | 武田药品工业株式会社 | Controlled release preparation |
US7790755B2 (en) | 2002-10-16 | 2010-09-07 | Takeda Pharmaceutical Company Limited | Controlled release preparation |
EP1462097A1 (en) * | 2003-03-28 | 2004-09-29 | Acme Drugs S.r.l. | Process for the preparation of enteric-coated and /or controlled-release medicaments containing active principles sensitive to gastrointestinal environment |
WO2005020954A3 (en) * | 2003-09-03 | 2005-11-03 | Agi Therapeutics Ltd | Proton pump inhibitor formulations, and methods of preparing and using such formulations |
WO2005020954A2 (en) * | 2003-09-03 | 2005-03-10 | Agi Therapeutics Limited | Proton pump inhibitor formulations, and methods of preparing and using such formulations |
US9889152B2 (en) | 2004-06-16 | 2018-02-13 | Takeda Pharmaceuticals U.S.A., Inc. | Multiple PPI dosage form |
US9238029B2 (en) | 2004-06-16 | 2016-01-19 | Takeda Pharmaceuticals U.S.A., Inc. | Multiple PPI dosage form |
WO2006049564A1 (en) * | 2004-11-04 | 2006-05-11 | Astrazeneca Ab | New modified release pellet formulations for proton pump inhibitors |
WO2006049565A1 (en) * | 2004-11-04 | 2006-05-11 | Astrazeneca Ab | New modified release tablet formulations for proton pump inhibitors |
EP1762231A1 (en) * | 2005-08-19 | 2007-03-14 | Verla-Pharm Arzneimittelfabrik Apotheker H.J. von Ehrlich GmbH & Co. KG | Sustained release magnesium microtablets |
WO2008002567A3 (en) * | 2006-06-27 | 2008-09-12 | Alza Corp | Methods of treating conditions by sustained release administration of benzimidazole derivatives |
WO2008002567A2 (en) * | 2006-06-27 | 2008-01-03 | Alza Corporation | Methods of treating conditions by sustained release administration of benzimidazole derivatives |
US9801824B2 (en) | 2008-09-09 | 2017-10-31 | Pozen Inc. | Method for delivering a pharmaceutical composition to patient in need thereof |
US9393208B2 (en) | 2008-09-09 | 2016-07-19 | Pozen Inc. | Method for delivering a pharmaceutical composition to patient in need thereof |
US9220698B2 (en) | 2008-09-09 | 2015-12-29 | Pozen Inc. | Method for delivering a pharmaceutical composition to patient in need thereof |
US8945621B2 (en) | 2009-06-25 | 2015-02-03 | Pozen Inc. | Method for treating a patient at risk for developing an NSAID-associated ulcer |
US10960052B2 (en) | 2010-12-16 | 2021-03-30 | Novo Nordisk A/S | Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl) amino) caprylic acid |
US11382957B2 (en) | 2010-12-16 | 2022-07-12 | Novo Nordisk A/S | Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid |
US11117947B2 (en) | 2011-04-12 | 2021-09-14 | Novo Nordisk A/S | Double-acylated GLP-1 derivatives |
US11034746B2 (en) | 2011-04-12 | 2021-06-15 | Novo Nordisk A/S | Double-acylated GLP-1 derivatives |
US9987231B2 (en) | 2011-12-28 | 2018-06-05 | Pozen Inc. | Compositions and methods for delivery of omeprazole plus acetylsalicylic acid |
US10603283B2 (en) | 2011-12-28 | 2020-03-31 | Genus Lifesciences, Inc. | Compositions and methods for delivery of omeprazole plus acetylsalicylic acid |
US9539214B2 (en) | 2011-12-28 | 2017-01-10 | Pozen Inc. | Compositions and methods for delivery of omeprazole plus acetylsalicylic acid |
US10933120B2 (en) | 2012-03-22 | 2021-03-02 | Novo Nordisk A/S | Compositions of GLP-1 peptides and preparation thereof |
EP2827845B1 (en) | 2012-03-22 | 2018-12-26 | Novo Nordisk A/S | Compositions comprising a delivery agent and preparation thereof |
US11123296B2 (en) | 2012-03-22 | 2021-09-21 | Novo Nordisk A/S | Compositions comprising a delivery agent and preparation thereof |
US11759502B2 (en) | 2012-03-22 | 2023-09-19 | Novo Nordisk A/S | Compositions of GLP-1 peptides and preparation thereof |
US11759503B2 (en) | 2012-03-22 | 2023-09-19 | Novo Nordisk A/S | Compositions of GLP-1 peptides and preparation thereof |
US11759501B2 (en) | 2012-03-22 | 2023-09-19 | Novo Nordisk A/S | Compositions of GLP-1 peptides and preparation thereof |
US11033499B2 (en) | 2012-06-20 | 2021-06-15 | Novo Nordisk A/S | Tablet formulation comprising a GLP-1 peptide and a delivery agent |
US11833248B2 (en) | 2018-02-02 | 2023-12-05 | Novo Nordisk A/S | Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid |
Also Published As
Publication number | Publication date |
---|---|
CA2383306A1 (en) | 2001-04-12 |
AU783911B2 (en) | 2005-12-22 |
TWI233363B (en) | 2005-06-01 |
GB9923436D0 (en) | 1999-12-08 |
JP2003510346A (en) | 2003-03-18 |
MXPA02003440A (en) | 2004-09-10 |
NZ518033A (en) | 2003-11-28 |
ZA200203486B (en) | 2003-08-04 |
HUP0203311A2 (en) | 2004-05-28 |
HUP0203311A3 (en) | 2004-06-28 |
EP1217992A1 (en) | 2002-07-03 |
CN1402630A (en) | 2003-03-12 |
AR025938A1 (en) | 2002-12-18 |
AU1020601A (en) | 2001-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU783911B2 (en) | Coated solid dosage forms | |
US8968777B2 (en) | Tranexamic acid formulations with reduced adverse effects | |
RU2240110C2 (en) | New preparation | |
US5540945A (en) | Pharmaceutical preparations for oral administration that are adapted to release the drug at appropriate sites in the intestines | |
JP2001526213A (en) | Oral drug pulse release dosage form | |
KR20070083956A (en) | New modified release tablet formulations for proton pump inhibitors | |
AU2018202652A1 (en) | Gastro-retentive drug delivery system | |
WO2005079748A2 (en) | Pharmaceutical preparation for sustained release of a pharmaceutically active ingredient | |
KR20180082613A (en) | A pharmaceutical composition comprising a potent inhibitor of URAT1 | |
KR20070036797A (en) | Dosage forms with an enterically coated core tablet | |
JP2008534681A (en) | Dipyridamole sustained release formulation and method for its preparation | |
WO1998026767A2 (en) | Site-specific controlled release dosage formulation for mesalamine | |
EP0425699B1 (en) | Oral preparation which can be released at suitable region in intestine | |
CN109152772B (en) | Oral pharmaceutical composition of nicotinamide | |
CZ298851B6 (en) | Controlled-release tablet for oral administration of active substances | |
AU2003218701A1 (en) | Medicaments containing active ingredients which lower the level of cholesterol with time-delayed active ingredient release | |
WO2017084680A1 (en) | Pharmaceutical composition containing a non-steroidal antiinflammatory drug and a proton pump inhibitor | |
EP1539113A2 (en) | Modified release ketoprofen dosage form | |
MXPA06001407A (en) | Composition for releasing a weak base for an extended period of time. | |
US8313775B2 (en) | Antibiotic product, use and formulation thereof | |
US8313776B2 (en) | Antibiotic product, use and formulation thereof | |
JP2005528388A (en) | Improved controlled release formulation | |
CN107224585B (en) | A composition comprising a non-steroidal anti-inflammatory drug and a proton pump inhibitor | |
WO2010036975A2 (en) | Dipyridamole and acetylsalicylic acid formulations and process for preparing same | |
KR20080110876A (en) | Oral pharmaceutical coated composition for pulsatile release |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
CFP | Corrected version of a pamphlet front page |
Free format text: REVISED TITLE RECEIVED BY THE INTERNATIONAL BUREAU AFTER COMPLETION OF THE TECHNICAL PREPARATIONS FOR INTERNATIONAL PUBLICATION |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000971305 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2383306 Country of ref document: CA Ref document number: 518033 Country of ref document: NZ |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 527776 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10206/01 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2002/003440 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002/03486 Country of ref document: ZA Ref document number: 200203486 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 008165831 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2000971305 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10110262 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 518033 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 518033 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 10206/01 Country of ref document: AU |